Mixed Connective Tissue Disease: Causes & Treatment

What is Mixed Connective Tissue Disease?

Mixed connective tissue disease (abbreviated MCTD) is a rare, chronic autoimmune disorder of the connective tissue. It was first described in 1972 by the American rheumatologist Gordon Sharp, which is why it is sometimes referred to as Sharp syndrome. The condition is characterized by overlapping features of several distinct connective tissue diseases, most notably systemic lupus erythematosus (SLE), systemic sclerosis (scleroderma), and polymyositis or dermatomyositis. A hallmark laboratory finding is the presence of high-titer antibodies against U1-ribonucleoprotein (anti-U1-RNP antibodies) in the blood.

Causes

The exact causes of MCTD are not yet fully understood. As an autoimmune disease, the immune system mistakenly attacks the body's own tissues. The following factors are considered potential contributors:

• Genetic predisposition: Certain HLA genotypes (human leukocyte antigens) are associated with an increased risk of developing MCTD.
• Hormonal influences: Women of childbearing age are disproportionately affected, suggesting a role for estrogen.
• Environmental triggers: Infections, UV radiation, or certain medications may act as disease triggers.
• Immunological dysregulation: A disruption in immune system regulation leads to the production of autoantibodies against cell nucleus components.

Symptoms

The symptoms of MCTD are diverse and can change over the course of the disease. Common manifestations include:

• Raynaud phenomenon: Exaggerated vascular response to cold or stress, causing color changes (white, blue, red) in the fingers. This is often one of the earliest signs.
• Joint complaints: Arthritis (joint inflammation) and arthralgia (joint pain), similar to rheumatoid arthritis.
• Muscle weakness: Inflammatory muscle disease (myositis) with weakness predominantly in the muscles around the shoulders and hips.
• Swollen hands: Characteristic puffy, sausage-like swelling of the fingers (dactylitis).
• Skin changes: Thickening and hardening of the skin, similar to scleroderma, as well as a butterfly-shaped facial rash as seen in lupus.
• Fatigue and general malaise: Chronic exhaustion, fever, and weight loss.
• Internal organ involvement: In advanced cases, the lungs (pulmonary hypertension, pulmonary fibrosis), heart, kidneys, and esophagus may be affected.

Diagnosis

Diagnosing MCTD can be challenging because its symptoms resemble those of other autoimmune diseases. The diagnostic process typically includes:

• Laboratory tests: Detection of anti-U1-RNP antibodies in high titers is the most important diagnostic marker. Antinuclear antibodies (ANA) are also measured.
• Clinical evaluation: Physical examination for typical features such as Raynaud phenomenon, swollen hands, arthritis, and myositis.
• Imaging: X-ray, ultrasound, MRI, or CT scans to assess joints, lungs, and other organs.
• Pulmonary function tests: To detect potential lung involvement.
• Diagnostic criteria: Various classification criteria exist (e.g., Sharp, Alarcón-Segovia, Kasukawa) and are used to support the diagnosis.

Treatment

There is currently no cure for MCTD. Treatment aims to control disease activity, relieve symptoms, and prevent organ damage. Therapy is individualized based on the severity of the disease and the organs involved.

Pharmacological Treatment

• Corticosteroids (e.g., prednisone): Used to quickly reduce inflammation during flares, but tapered over time due to side effects.
• Antimalarials (e.g., hydroxychloroquine): A cornerstone therapy with anti-inflammatory properties, especially for skin and joint involvement.
• Immunosuppressants (e.g., methotrexate, azathioprine, mycophenolate): Used for severe organ manifestations or when the response to corticosteroids is inadequate.
• Calcium channel blockers (e.g., nifedipine): Used to treat the Raynaud phenomenon.
• Endothelin receptor antagonists or phosphodiesterase-5 inhibitors: Used for pulmonary arterial hypertension.

Non-Pharmacological Measures

• Physiotherapy and occupational therapy to maintain mobility and muscle strength.
• Cold protection to prevent Raynaud attacks.
• Regular medical check-ups for early detection of organ involvement.
• Patient education and psychosocial support.

Prognosis

The course of MCTD varies considerably between patients. Many individuals experience a mild disease course and can lead a good quality of life with appropriate treatment. A significant risk factor is pulmonary arterial hypertension (high blood pressure in the lung vessels), which is the leading cause of death in MCTD. Regular monitoring and early treatment are essential for a favorable long-term outcome.

References

1. Alarcón-Segovia D, Villarreal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds.). Mixed Connective Tissue Disease and Anti-nuclear Antibodies. Amsterdam: Elsevier, 1987.
2. Gunnarsson R, Hetlevik SO, Lilleby V, Molberg Ø. Mixed connective tissue disease. Best Practice & Research Clinical Rheumatology. 2016;30(1):95-111. PubMed PMID: 27421219.
3. Hajas A, Szodoray P, Nakken B, et al. Clinical course, prognosis, and causes of death in mixed connective tissue disease. Journal of Rheumatology. 2013;40(7):1134-1142. PubMed PMID: 23637328.